NCM · Biotechnology

RLMD (RLMD) Stock

$5.20 +0.39% NCM: RLMD Healthcare

Valuation

MetricValue
Price$5.20
Market Cap$545.43M
P/E Ratio-5.12
P/B Ratio8.93
P/S Ratio0.00
EPS (TTM)$-1.45
52-Week High$8.00
52-Week Low$0.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-65.52%
ROA-60.64%
ROCE-67.82%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio15.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-126.0M$-161.0M$-104.0M$-84.0M$-59.0M
Net Profit$-126.0M$-157.0M$-99.0M$-80.0M$-57.0M
EPS$-7.16$-5.30$-3.28$-2.65$-1.45
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$223.0M$153.0M$98.0M$46.0M$94.0M
Total Liabilities$15.0M$12.0M$12.0M$10.0M$7.0M
Cash$44.0M$5.0M$4.0M$4.0M$3.0M
Borrowings$0$0$0$0$0

Latest News

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 GlobeNewswire · Jul 16, 2026 Relmada Therapeutics Joins Russell 2000, Russell 3000 Indexes MT Newswires · Jun 29, 2026 Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes GlobeNewswire · Jun 29, 2026 Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now Insider Monkey · Jun 19, 2026 HC Wainwright Initiates Relmada Therapeutics at Buy With $12 Price Target MT Newswires · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-92.0M$-104.0M$-52.0M$-52.0M$-46.0M
Investing Cash Flow$-54.0M$20.0M$50.0M$52.0M$-48.0M
Financing Cash Flow$3.0M$2.0M$0$0$0
Net Cash Flow$42.0M$-39.0M$-1.0M$0$0
Free Cash Flow$-92.0M$-104.0M$-52.0M$-52.0M$-46.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-9.20%
Quick Ratio18.26
Interest Coverage—
Return 1Y623.23%
Return 3Y83.10%
Return 5Y-80.32%

Ownership

Insiders Held2.90%
Institutions Held91.38%
Institutions Float Held94.11%
Institutional HolderSharesReport Date
Squadron Capital Management LLC8,474,5712026-03-31
Spruce Street Capital LP6,262,1142026-03-31
Venrock Adviser, LLC4,843,3802026-03-31
Adage Capital Partners GP L.L.C.4,763,1582026-03-31
Orbimed Advisors LLC.4,715,8642026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACET $8.30 +1.22% -0.46 $77.59M 0.00%
ACRV $1.73 +2.37% -0.95 $74.05M 0.00%
CBUS $1.93 +0.00% -0.50 $87.79M 0.00%
FBIO $2.67 -3.61% 0.91 $88.69M 0.00%
IMUXImmunic, Inc. $13.81 +3.14% -2.24 $188.11M 0.00%

About RLMD

RLMD is led by CEO Sergio Traversa, publicly traded since 2014.

RLMD stock trades at $5.20 with a market capitalization of $545.43M. The stock is valued at a price-to-earnings (P/E) ratio of -5.12, price-to-book of 8.93, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.52 and $8.00, and currently trades 35.0% below its 52-week high.

On profitability, RLMD generates a return on equity (ROE) of -65.52%, return on capital employed of -67.82%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides